Late angiographic stent thrombosis: The LAST straw for drug-eluting stents?

Angiology

Volumn 59, Issue 6, 2009, Pages 667-675

  Chen, Jack P ^a,c   Crisco, Larry V ^c   Jabara, Refat ^a   King III, Spencer B ^b  

^a Saint Joseph's Hospital of Atlanta   (United States)

^b PIEDMONT HOSPITAL   (United States)

^c NONE

Author keywords

Angioplasty; Coronary intervention; Drug eluting; Late; Stent; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PACLITAXEL; RAPAMYCIN;

BARE METAL STENT; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG ELUTING STENT; FOOD AND DRUG ADMINISTRATION; HUMAN; LATE ANGIOGRAPHIC STENT THROMBOSIS; MONOTHERAPY; PATHOPHYSIOLOGY; RESTENOSIS; REVASCULARIZATION; REVIEW; RISK ASSESSMENT; SAFETY; STENT THROMBOSIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ANGIOGRAPHY; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; EVIDENCE-BASED MEDICINE; GUIDELINE ADHERENCE; HUMANS; MYOCARDIAL ISCHEMIA; PATIENT SELECTION; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PROSTHESIS DESIGN; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME; VASCULAR PATENCY;

EID: 57849091324     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319707310279     Document Type: Review

References (46)

1. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002 ; 346: 1773-1780.
2. Moses JW, Leon MB, Popma JJ,, et al. and SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003 ; 349: 1315-1323.
3. Stone GW, Ellis SG, Cox DA,, et al. and Taxus-Iv Investigators. A polymer-based paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004 ; 350: 221-231.
4. Serruys P. Arterial revascularization therapies study part II of the sirolimus-eluting stent in the treatment of patients with multivessel de novo coronary artery lesions [abstract]. J Am Coll Cardiol. 2005 ; 45 (suppl A): 7A.
5. Ong AT, Hoye A., Aoki J., et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol. 2005 ; 45: 947-953.
6. Camenzind E. Address at Joint Session of the European Society of Cardiology and the World Heart Federation ; September 2006 ; Barcelona, Spain.
7. Faxon DP Debate: Should drug-eluting stent use be curtailed in the milieu of mounting safety concerns? Transcatheter Cardiovascular Therapeutics Annual Meeting ; September 2006. Washington, DC.
8. Pfisterer ME, Brunner-La Rocca HP, Buser PT,, et al. and Basket-Late Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006 ; 48: 2584-2591.
9. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007 ; 356: 998-1008.
10. Baim DS Update-DES Stent Thrombosis and Long-Term Safety Profile. (Monogram). Natick, MA: Boston Scientific Corporation ; 2006.
11. Baim DS Late Stent Thrombosis With Drug-Eluting Coronary Stents. Natick, MA: Boston Scientific Corporation ; 2007.
12. Lagerqvist B., James SK, Stenestrand U.,, et al. for the SCAAR Study Group. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007 ; 35: 1009-1019.
13. Fajadet J., Morice M. -C, Bode C., et al. Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial. Circulation. 2005 ; 111: 1040-1044.
14. Jensen LO, Maeng M., Kaltoft A., et al. Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions. J Am Coll Cardiol. 2007 ; 50: 463-470.
15. Kastrati A., Mehilli J., Pache J., et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007 ; 356: 1030-1039.
16. Holmes DR, Kereiakes DJ, Laskey WK, et al. Thrombosis and drug-eluting stents: an objective appraisal. J Am Coll Cardiol. 2007 ; 50: 109-118.
17. Ong AT, van Domburg RT, Aoki J., et al. Sirolimus-eluting stents remain superior to bare-metal stents at two years: medium-term results from the rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital (RESEARCH) Registry. J Am Coll Cardiol. 2006 ; 47: 1356-1360.
18. Weisz G., Leon MB, Holmes DR Jr, et al. Two-year outcomes after sirolimus-eluting stent implantation. J Am Coll Cardiol. 2006 ; 47: 1350-1355.
19. Boden WE Understanding Systemic Atherothrombosis: Pathophysiology and Epidemiology of Risk in Long-Term Antiplatelet Therapy: Patient Selection, Therapeutic Choices. (Monogram). New York, NY: Academy of Healthcare, Inc; 2006.
20. Hong MK, Mintz GS, Lee CW,, et al. and Asian Paclitaxel-Eluting Stent Clinical Trial Investigators. Paclitaxel coating reduces in-stent intimal hyperplasia in human coronary arteries: a serial volumetric intravascular ultrasound analysis from the Asian Paclitaxel-Eluting Stent Clinical Trial (ASPECT). Circulation. 2003 ; 107: 517-520.
21. Kotani J. -I, Awata M., Nanto S., et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol. 2006 ; 47: 2108-2111.
22. Buonamici P., Marcucci R., Migliorini A., et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol. 2007 ; 49: 2312-2317.
23. Nebeker JR, Virmani R., Bennett CL, et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol. 2006 ; 47: 175-181.
24. Virmani R., Guagliumi G., Farb, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation. 2004 ; 109: 701-705.
25. Dibra A., Kastrati A., Mehilli J., et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med. 2005 ; 353: 663-670.
26. Kastrati A., Dibra A., Eberle S., et al. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. JAMA. 2005 ; 294: 819-825.
27. Windecker S., Remondino A., Wenaweser P., et al. A randomized comparison of a sirolimus with a paclitaxel eluting stent for coronary revascularization: the SIRTAX trial [abstract]. J Am Coll Cardiol 2005 ; 45 (suppl A): 7A.
28. Kandzari D., O'Neill W., Strauss W. One-year outcomes from the TC-WYRE Registry: Taxus express stent versus cypher stent: what's your real-world experience? E-poster presented at: Transcatheter Cardiovascular Therapeutics Annual Meeting ; October 2006 ; Washington, DC.
29. Silber S. Debate: Should drug-eluting stent use be curtailed in the milieu of mounting safety concerns? Transcatheter Cardiovascular Therapeutics ; September 2006 ; Washington, DC.
30. Berger A., Stauffer J-C., Seydoux C. Three-year follow-up of the first prospective randomized comparison between paclitaxel and sirolimus stents: the TAXi-LATE Trial. Catheter Cardiovasc Interv. 2007 ; 70: 163-166.
31. Cosgrave J., Melzi G., Corbett S., et al. Comparable clinical outcomes with paclitaxel- and sirolimus-eluting stents in unrestricted contemporary practice. J Am Coll Cardiol. 2007 ; 49: 2320-2328.
32. Spertus JA, Kettelkamp R., Vance C., et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation. 2006 ; 113: 2803-2809.
33. Chen JP Very late drug-eluting stent thrombosis and cardiogenic shock: 1,249 days after implantation. J Invasive Cardiol. 2007 ; 19: e381 - e384.
34. Stabile E., Cheneau E., Kinnaird T., et al. Late thrombosis in cypher stents after the discontinuation of antiplatelet therapy. Cardiovasc Rad Med. 2004 ; 5: 173-176.
35. Ong AT, McFadden EP, Regar E., et al. Late Angiographic Stent Thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol. 2005 ; 45: 2088-2092.
36. Artang R., Dieter RS Analysis of 36 reported cases of late thrombosis in drug-eluting stents placed in coronary arteries. Am J Cardiol. 2007 ; 99: 1039-1043.
37. Machecourt J., Danchin N., Lablanche JM, et al. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients. The EVASTENT matched-cohort registry. J Am Coll Cardiol. 2007 ; 50: 501-508.
38. Rabbat MG, Bavry AA, Bhatt DL, et al. Understanding and minimizing late thrombosis of drug-eluting stents. Cleve Clin J Med. 2007 ; 74: 129-136.
39. Grines CL, Bonow RO, Casey DE, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents. A science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation. 2007 ; 115: 1-6.
40. Serruys PW, Ong AT, Piek JJ A randomized comparison of durable polymer Everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial. Euro Interv. 2005 ; 1: 58-65.
41. Grube E., Hauptmann KE, Buellesfeld. Six-month results of a randomized study to evaluate safety and efficacy of a Biolimus A9 eluting stent with a biodegradable polymer coating. Euro Interv. 2005 ; 1: 53-57.
42. Fajadet J., Wijns W., Laarman GJ, et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine- encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation. 2006 ; 114: 798-806.
43. Chen MS, John JM, Chew DP, et al. Bare metal stent restenosis is not a benign clinical entity. Am Heart J. 2006 ; 151: 1260-1264.
44. Stone GW, Ellis SG, Colombo A., et al. Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation. Circulation. 2007 ; 115: 2842-2847.
45. Moreno R., Fernandez C., Calvo L., et al. Meta-analysis comparing the effect of drug-eluting versus bare metal stents on risk of acute myocardial infarction during follow-up. Am J Cardiol. 2007 ; 99: 621-625.
46. US Food and Drug Administration CDRH. Update to FDA Statement on Coronary Drug-Eluting Stents. http://www.fda.gov/cdrh/news/010407.html. Accessed November 2, 2007.